{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T19:55:22Z","timestamp":1777924522252,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Technology and Health Care"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Low-concentration atropine sulfate eye drops (LAED) are widely used in children to control myopia progression; however, their long-term safety and effects on children's development remain unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the safety and growth development effects of LAED in juvenile cynomolgus monkeys over one year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eighty-eight juvenile cynomolgus monkeys were randomly assigned to a negative control group or one of three treatment groups receiving daily LAED: 0.01\u2005mg (0.01%), 0.02\u2005mg (0.01%), or 0.08\u2005mg (0.04%) per day, with 22 animals (11 males and 11 females) per group. The treatment period lasted 12 months, followed by a 2-month recovery observation. Toxicological, growth, and ophthalmological parameters were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No test substance-related changes were observed in food intake, body weight, body temperature, hematology, biochemical parameters, immunoglobulins, ECGs, blood pressure, urinalysis, bone marrow, or histopathology across all groups. Growth parameters exhibited age-consistent upward trends. The 0.04% LAED dose caused transient pupil dilation throughout the treatment period, which resolved upon withdrawal, attributed to the pharmacological effects of atropine sulfate. Toxicokinetic analysis revealed minimal systemic exposure, with no evidence of drug accumulation after prolonged use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The no-observed-adverse-effect level (NOAEL) for 0.04% LAED (0.8\u2005mg\/monkey\/day) in juvenile cynomolgus monkeys was established over a one-year period. No developmental or ocular toxicity was observed, providing a foundation for the clinical evaluation of LAED in delaying myopia progression in children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/09287329251340497","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T03:13:12Z","timestamp":1747883592000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect and safety assessment of low-concentration atropine eye drops on the growth and development of juvenile cynomolgus monkeys over a period of one year"],"prefix":"10.1177","author":[{"given":"Jianmin","family":"Guo","sequence":"first","affiliation":[{"name":"Guangzhou Bay Area Institute of Biomedicine, Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, State Key Laboratory of Ophthalmology, Guangdong Provincial Center for Ophthalmic Drug Creation and Evaluation Engineering Technology, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangzhou, China"},{"name":"Division of Life Science and State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Hong Kong SAR, China"},{"name":"College of Pharmacy, Guilin Medical University, Guilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuankeng","family":"Huang","sequence":"additional","affiliation":[{"name":"Guangzhou Bay Area Institute of Biomedicine, Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, State Key Laboratory of Ophthalmology, Guangdong Provincial Center for Ophthalmic Drug Creation and Evaluation Engineering Technology, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junli","family":"Lin","sequence":"additional","affiliation":[{"name":"Guangzhou Bay Area Institute of Biomedicine, Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, State Key Laboratory of Ophthalmology, Guangdong Provincial Center for Ophthalmic Drug Creation and Evaluation Engineering Technology, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[{"name":"Guangzhou Bay Area Institute of Biomedicine, Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, State Key Laboratory of Ophthalmology, Guangdong Provincial Center for Ophthalmic Drug Creation and Evaluation Engineering Technology, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xialing","family":"Lei","sequence":"additional","affiliation":[{"name":"Guangzhou Bay Area Institute of Biomedicine, Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, State Key Laboratory of Ophthalmology, Guangdong Provincial Center for Ophthalmic Drug Creation and Evaluation Engineering Technology, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinlong","family":"Dai","sequence":"additional","affiliation":[{"name":"Guangzhou Bay Area Institute of Biomedicine, Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, State Key Laboratory of Ophthalmology, Guangdong Provincial Center for Ophthalmic Drug Creation and Evaluation Engineering Technology, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lang","family":"Huang","sequence":"additional","affiliation":[{"name":"Guangzhou Bay Area Institute of Biomedicine, Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, State Key Laboratory of Ophthalmology, Guangdong Provincial Center for Ophthalmic Drug Creation and Evaluation Engineering Technology, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujiao","family":"Li","sequence":"additional","affiliation":[{"name":"Guangzhou Bay Area Institute of Biomedicine, Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, State Key Laboratory of Ophthalmology, Guangdong Provincial Center for Ophthalmic Drug Creation and Evaluation Engineering Technology, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Lin","sequence":"additional","affiliation":[{"name":"Guangzhou Bay Area Institute of Biomedicine, Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, State Key Laboratory of Ophthalmology, Guangdong Provincial Center for Ophthalmic Drug Creation and Evaluation Engineering Technology, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangzhou, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangzhou Bay Area Institute of Biomedicine, Guangdong Provincial Key Laboratory of Drug Non-Clinical Evaluation and Research, State Key Laboratory of Ophthalmology, Guangdong Provincial Center for Ophthalmic Drug Creation and Evaluation Engineering Technology, Guangdong Lewwin Pharmaceutical Research Institute Co., Ltd., Guangzhou, China"},{"name":"Division of Life Science and State Key Laboratory of Molecular Neuroscience, Hong Kong University of Science and Technology, Hong Kong SAR, China"},{"name":"College of Pharmacy, Guilin Medical University, Guilin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"e_1_3_2_2_2","article-title":"Myopia - a 21st century public health issue","volume":"60","author":"Resnikoff S","year":"2019","unstructured":"Resnikoff S, Jonas JB, Friedman D, et\u00a0al. Myopia - a 21st century public health issue. Invest Ophth Vis Sci 2019; 60: Mi\u2013Mii.","journal-title":"Invest Ophth Vis Sci"},{"key":"e_1_3_2_3_2","first-page":"399","article-title":"Prevalence and time trends of myopia in children and adolescents in China: a systemic review and meta-analysis","volume":"40","author":"Dong L","year":"2020","unstructured":"Dong L, Kang YK, Li Y, et\u00a0al. Prevalence and time trends of myopia in children and adolescents in China: a systemic review and meta-analysis. Retina-J Ret Vit Dis 2020; 40: 399\u2013411.","journal-title":"Retina-J Ret Vit Dis"},{"key":"e_1_3_2_4_2","first-page":"5","article-title":"High myopia and its risks","volume":"32","author":"Williams K","year":"2019","unstructured":"Williams K, Hammond C. High myopia and its risks. Community Eye Health 2019; 32: 5\u20136.","journal-title":"Community Eye Health"},{"key":"e_1_3_2_5_2","first-page":"527","article-title":"The control of myopia with atropine","volume":"8","author":"Gimbel HV","year":"1973","unstructured":"Gimbel HV. The control of myopia with atropine. Can J Ophthalmol 1973; 8: 527\u2013532.","journal-title":"Can J Ophthalmol"},{"key":"e_1_3_2_6_2","first-page":"891","article-title":"The effect of atropine on myopia","volume":"3","author":"Bedrossian RH","year":"1971","unstructured":"Bedrossian RH. The effect of atropine on myopia. Ann Ophthalmol 1971; 3: 891\u2013897.","journal-title":"Ann Ophthalmol"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.031"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.10.016"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.24162"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-023-04921-5"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.07.004"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612821666150909095403"},{"key":"e_1_3_2_13_2","first-page":"58","article-title":"An overview of the dosage, side effects, and long-term effects of atropine eye drops in management of myopia progression in children","volume":"7","author":"Mohammad HA","year":"2024","unstructured":"Mohammad HA, Shafie NAGS. An overview of the dosage, side effects, and long-term effects of atropine eye drops in management of myopia progression in children. Asian J Res Rep Ophthalmol 2024; 7: 58\u201363.","journal-title":"Asian J Res Rep Ophthalmol"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.21037\/qims-21-799"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.120.000483"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00441-x"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxrep.2023.02.014"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000634"},{"key":"e_1_3_2_19_2","article-title":"Biological basis of child health 11: anatomy, physiology and development of the senses","author":"Davies K","year":"2021","unstructured":"Davies K. Biological basis of child health 11: anatomy, physiology and development of the senses. Nurs Child Young People 2021.\u00a0doi: 10.7748\/ncyp.2021.e1322. Online ahead of print.","journal-title":"Nurs Child Young People"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15102431"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/10543406.2023.2172425"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1177\/1091581817699975"}],"container-title":["Technology and Health Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09287329251340497","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/09287329251340497","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/09287329251340497","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T21:26:00Z","timestamp":1777670760000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/09287329251340497"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":21,"alternative-id":["10.1177\/09287329251340497"],"URL":"https:\/\/doi.org\/10.1177\/09287329251340497","relation":{},"ISSN":["0928-7329","1878-7401"],"issn-type":[{"value":"0928-7329","type":"print"},{"value":"1878-7401","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]},"article-number":"09287329251340497"}}